Atlas Trials

CD19 Redirected Autologous T Cells for Hodgkin Lymphoma

Clinical trial NCT02277522 · TERMINATED

Trial details

NCT number
NCT02277522
Sponsor
University of Pennsylvania
Status
TERMINATED
Phase
Early Phase 1
Study type
INTERVENTIONAL
Hodgkin Lymphoma With no Available Curative Treatment Options Who Have a Limited Prognosis
Start date
2014-10-01
Primary completion
2016-11-01
Enrollment
4

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.